Preliminary results from a large clinical trial showed Roche's rheumatoid arthritis drug Actemra, or tocilizumab, can reduce mortality risk among hospitalized patients with severe COVID-19, particularly when taken together with the steroid dexamethasone. The findings also showed tocilizumab can shorten hospital length of stay and reduce the need for mechanical ventilation.
RA drug cuts death risk in patients with severe COVID-19
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.